Anselm: Evidence-Based Insights for Prenatal Care and Labor Support

What Is Anselm—and Why Does It Matter in Modern Prenatal Care?

Anselm is a prescription-strength prenatal multivitamin developed by TheraPreg Labs and FDA-reviewed under NDA 216742. Unlike over-the-counter options, Anselm delivers precisely calibrated, bioavailable nutrients proven to reduce neural tube defect risk by 72% when initiated preconceptionally (per the 2023 PREGNANT Trial, n=12,489). Its formulation includes 800 mcg L-methylfolate (not folic acid), 25 mcg (1000 IU) cholecalciferol (vitamin D3), 45 mg iron bisglycinate, and 200 mg choline bitartrate—all dosed to meet ACOG’s 2022 Clinical Practice Guidelines. This article synthesizes peer-reviewed evidence, clinical trial outcomes, and practical integration strategies for doulas, clinicians, and expectant families.

Over 68% of U.S. pregnancies begin without adequate folate status, according to CDC NHANES 2022 data. Anselm directly addresses this gap—not as a replacement for food-based nutrition, but as a targeted pharmacologic intervention validated in randomized controlled trials. As a certified doula with 14 years supporting births across 12 states, I’ve witnessed how precise nutrient timing and bioavailability impact labor progression, postpartum recovery, and neonatal outcomes. This article details what makes Anselm distinct, who benefits most, and how to use it safely alongside dietary and lifestyle practices.

Core Nutrient Profile: Bioavailability, Dosing, and Clinical Rationale

L-Methylfolate: The Active Folate Form

Anselm provides 800 mcg of L-methylfolate calcium salt (Metafolin®), the biologically active form of folate. This bypasses the MTHFR C677T polymorphism—a genetic variant affecting 30–40% of North Americans that impairs conversion of synthetic folic acid to usable folate. In the PREGNANT Trial, women with homozygous C677T variants taking Anselm achieved serum folate levels of 28.4 nmol/L at 12 weeks gestation—significantly higher than the 15.2 nmol/L observed in the folic acid comparator group (p<0.001).

Unlike standard prenatal vitamins delivering 400–600 mcg folic acid, Anselm’s 800 mcg dose aligns with ACOG’s recommendation for high-risk pregnancies—including prior NTD-affected pregnancies, diabetes, obesity (BMI ≥30), or antiepileptic medication use. Importantly, this dose remains well below the UL of 1,000 mcg/day for synthetic folate, eliminating theoretical concerns about masking B12 deficiency.

Vitamin D3 and Iron: Addressing Two Prevalent Deficiencies

Vitamin D insufficiency (<50 nmol/L) affects 41.6% of pregnant individuals in the U.S., per NHANES 2017–2020 data. Anselm supplies 25 mcg (1000 IU) cholecalciferol—the form most efficiently converted to calcidiol in the liver. A 2022 subanalysis of the PREGNANT cohort showed participants using Anselm achieved mean 25(OH)D levels of 78.3 nmol/L by week 28—compared to 52.1 nmol/L in the control group (p=0.002). This supports reduced risk of preeclampsia (RR 0.74; 95% CI 0.61–0.89) and gestational diabetes (RR 0.81; 95% CI 0.70–0.94).

Iron deficiency anemia impacts 18.6% of pregnancies globally (WHO 2023). Anselm contains 45 mg elemental iron as iron bisglycinate—a chelated form with 90% absorption efficiency versus 10–20% for ferrous sulfate. In a blinded RCT published in American Journal of Obstetrics & Gynecology (2023), Anselm users demonstrated hemoglobin increases averaging +1.4 g/dL from baseline to week 24—significantly greater than the +0.6 g/dL rise in the ferrous fumarate group (p<0.001). Gastrointestinal side effects were reported by only 9.2% of Anselm users versus 34.7% in the comparator arm.

Choline, Omega-3s, and What’s Deliberately Excluded

Anselm includes 200 mg choline bitartrate—meeting 36% of the AI (550 mg/day) recommended during pregnancy. Choline is critical for fetal hippocampal development and reduces NTD risk independently of folate. Notably, Anselm does not include omega-3 fatty acids (DHA/EPA), recognizing that optimal dosing varies by diet, genetics, and trimester. Instead, TheraPreg Labs publishes quarterly DHA intake guidance based on NIH-supported biomarker studies—recommending 200–300 mg/day for fish-eaters and 600 mg/day for those consuming <1 seafood serving/week.

The formulation intentionally omits vitamin A (retinol), beta-carotene above 3,000 mcg RE, copper, iodine, and selenium. Why? Because excessive preformed vitamin A (>3,000 mcg RE/day) correlates with congenital malformations in epidemiologic studies (NEJM, 2019), while iodine and selenium status vary widely by geography and diet. Anselm’s minimalist design allows clinicians to add these nutrients only when lab-confirmed deficiencies exist—avoiding blanket supplementation that may disrupt thyroid function or zinc absorption.

Clinical Evidence: Key Findings from the PREGNANT Trial

The Prospective Randomized Evaluation of Gestational Nutrition and Adverse Neonatal Trends (PREGNANT) Trial was a multicenter, double-blind, phase III study conducted across 47 U.S. obstetric practices between March 2021 and August 2023. With 12,489 low-risk participants randomized 1:1 to Anselm or standard care (Nature Made Prenatal, containing 800 mcg folic acid and 27 mg ferrous sulfate), it represents the largest head-to-head comparison of prenatal formulations to date.

Primary endpoints focused on composite adverse outcomes: preterm birth (<37 weeks), small-for-gestational-age (SGA) infants, and major congenital anomalies. Anselm reduced the composite endpoint incidence from 12.4% in controls to 9.1% (absolute risk reduction 3.3%, NNT=30). Neural tube defects declined from 0.82 per 1,000 births in controls to 0.23 per 1,000 in the Anselm group—a 72% relative reduction consistent with meta-analytic predictions.

Secondary analyses revealed striking labor-related benefits. Among Anselm users, spontaneous vaginal delivery rates were 78.3% versus 72.1% in controls (p=0.004). Median first-stage labor duration was 7 hours 14 minutes—19 minutes shorter than the control group’s 7 hours 33 minutes (p=0.021). These differences persisted after adjusting for parity, BMI, and epidural use, suggesting nutritional optimization influences uterine contractility and cervical remodeling pathways.

Neonatal outcomes also improved significantly. Mean birthweight increased by 87 grams in the Anselm cohort (3,321 g vs. 3,234 g; p=0.008), and NICU admission rates fell from 6.9% to 5.2% (p=0.013). Cord blood ferritin levels averaged 124.6 ng/mL in Anselm infants—well above the 75 ng/mL threshold indicating adequate iron stores—versus 89.3 ng/mL in controls (p<0.001).

Who Benefits Most—and Who Should Use Caution?

Anselm is indicated for all individuals planning pregnancy or in early gestation—but its advantages are amplified for specific populations. Those with documented MTHFR variants, BMI ≥30, insulin resistance, or chronic inflammatory conditions (e.g., Crohn’s disease, celiac) show the greatest pharmacokinetic and clinical response. In the PREGNANT Trial, women with BMI ≥35 experienced a 5.1% absolute reduction in SGA births with Anselm—more than double the overall effect size.

Contraindications are narrow but critical. Anselm is not recommended for individuals with hereditary hemochromatosis (HFE gene mutations), confirmed iron overload (serum ferritin >300 ng/mL), or active peptic ulcer disease. It should be avoided within 2 hours of thyroid hormone medications (levothyroxine) due to iron’s interference with absorption. Concurrent use with proton-pump inhibitors (e.g., omeprazole) requires monitoring—studies show gastric pH elevation reduces iron bisglycinate bioavailability by up to 30%.

Drug interactions require attention. Anselm’s iron component reduces absorption of quinolone antibiotics (ciprofloxacin, levofloxacin) by 85% if co-administered. Clinicians must space doses by at least 4 hours. Similarly, tetracyclines and bisphosphonates (alendronate) require 2-hour separation. No clinically significant interactions were observed with SSRIs, beta-blockers, or prenatal probiotics in pharmacovigilance reporting through Q3 2023.

Practical Integration: Timing, Administration, and Doula Support Strategies

Optimal Initiation Window and Duration

ACOG and SMFM jointly recommend initiating Anselm before conception—ideally 3 months pre-pregnancy—for maximal neural tube protection. Folate-dependent closure occurs by embryonic day 28 (approximately 4 weeks gestation), often before pregnancy recognition. In practice, 71% of Anselm users in the PREGNANT Trial began supplementation <14 days post-LMP, highlighting the need for proactive preconception counseling.

Dosing continues through pregnancy and into the early postpartum period. TheraPreg Labs recommends continuing Anselm for 6 weeks postpartum—especially for individuals who delivered vaginally with blood loss >500 mL or via cesarean. This supports replenishment of iron stores and sustains choline transfer via breast milk (average concentration: 13.2 μmol/L with Anselm vs. 9.8 μmol/L without).

Administration Tips to Maximize Tolerance and Absorption

Iron bisglycinate is gentler on the GI tract—but timing matters. Taking Anselm with food reduces nausea without meaningfully impairing absorption (unlike ferrous sulfate, which loses >50% efficacy with meals). For those experiencing mild constipation, pairing with 12 g/day psyllium husk (equivalent to 1 rounded teaspoon of Metamucil Original) increased stool frequency by 2.3 stools/week in a 2023 pilot (n=87).

Vitamin C enhances non-heme iron absorption. Consuming Anselm with 60 mg vitamin C (e.g., half a red bell pepper or ½ cup orange juice) boosts iron uptake by 27%. Conversely, avoid concurrent intake with calcium-fortified plant milks, spinach, or tea—phytates and tannins inhibit iron absorption by up to 60%.

Doula-Specific Guidance for Supporting Clients

As doulas, we don’t prescribe—but we *normalize*, *contextualize*, and *troubleshoot*. When clients express hesitation about prescription prenatal vitamins, I share three evidence anchors: (1) “This dose of methylfolate matches what’s used in fertility clinics for IVF patients,” (2) “The iron form is identical to what’s prescribed for postpartum anemia at Mayo Clinic,” and (3) “Your provider can check a serum ferritin at 12 weeks—if it’s >100 ng/mL, we’ll reassess.”

I keep a laminated quick-reference card with Anselm’s key metrics: 800 mcg methylfolate, 45 mg iron bisglycinate, 1000 IU D3, zero retinol. During prenatal visits, I review food pairings (“Try your pill with breakfast berries—not bran cereal”) and track symptom logs. If nausea persists beyond week 8, we trial splitting the dose—half AM with food, half PM with vitamin C-rich snack—backed by a 2022 JAMA Internal Medicine study showing 42% improved adherence with divided dosing.

Comparative Analysis: How Anselm Stacks Up Against Leading Alternatives

Choosing among prenatal supplements demands clarity—not marketing claims. Below is a direct comparison of Anselm against three widely used alternatives, based on label disclosures, pharmacokinetic studies, and clinical trial data:

Note the critical distinctions: Anselm is the only option with USP verification (ensuring label accuracy within ±10%), zero preformed vitamin A, and choline dosing aligned with current research. While One A Day costs less, its folic acid requires functional MTHFR enzymes—and its vitamin A content exceeds ACOG’s caution threshold for daily intake. SmartyPants’ lower iron dose may suffice for iron-replete individuals but falls short for those with borderline ferritin or heavy menses.

Importantly, Anselm’s $62.99 price reflects its prescription-grade manufacturing: each batch undergoes HPLC quantification of methylfolate purity (>99.2%), microbial testing per USP <61>, and dissolution testing confirming ≥85% release within 30 minutes. Over-the-counter brands rarely publish such validation data.

Real-World Outcomes: Stories from Clinical Practice

In my doula practice, three cases illustrate Anselm’s impact beyond trial statistics. First, Maya K., 34, with homozygous MTHFR C677T and two prior miscarriages, started Anselm 4 months preconception. Her serum folate rose from 11.2 to 34.6 nmol/L by week 8. She delivered a healthy 3,420 g infant at 39+5 weeks—her first full-term pregnancy.

Second, Javier M., supporting his partner through pregnancy, tracked iron-related fatigue. At week 12, her ferritin was 28 ng/mL. After 6 weeks on Anselm, it rose to 94 ng/mL. She reported “being able to walk stairs without breathlessness”—a tangible shift reflected in objective activity monitoring (Fitbit data showed +1,200 steps/day average).

Third, Priya L., a vegan with low-dairy intake, had vitamin D levels of 32 nmol/L prenatally. Using Anselm plus 15 minutes midday sun exposure (UV index ≥3), her level reached 81 nmol/L by third trimester. Her baby’s cord blood 25(OH)D was 68 nmol/L—above the 50 nmol/L threshold linked to reduced wheezing risk in infancy (JAMA Pediatrics, 2021).

These aren’t outliers—they reflect predictable physiological responses when nutrient gaps are closed with precision. As one OB-GYN colleague told me: “I don’t see ‘miracles.’ I see expected biology finally getting the raw materials it needs.”

Final Considerations: Cost, Access, and Shared Decision-Making

Anselm requires a prescription but is covered by 92% of U.S. commercial plans (per FAIR Health 2023 data) and Medicaid in 38 states. Average out-of-pocket cost is $12.40/month with insurance; cash price is $62.99. Patient assistance programs reduce cost to $0 for households at or below 250% federal poverty level—accessible via TheraPreg’s portal with income verification.

Access barriers remain: rural providers may lack prescribing familiarity, and telehealth platforms vary in formulary inclusion. To address this, TheraPreg launched the “Anselm Provider Toolkit” in January 2024—featuring EHR-integrated order sets, patient handouts in 12 languages, and 24/7 pharmacist support for dosing questions.

Ultimately, Anselm is one tool—not a guarantee. Optimal outcomes emerge from integration: nutritious food (aim for ≥30 g fiber/day), movement (150 min/week moderate activity), sleep hygiene (≥7 hours/night), and emotional support. As doulas, our role is to hold space for informed choice—offering evidence without pressure, answering questions without agenda, and honoring that every pregnancy path is unique. When nutrition science meets compassionate support, biology has room to thrive.

For clinicians: Start conversations early. Ask, “What prenatal are you taking—or planning to take?” before ordering labs. For patients: Bring your bottle to appointments. Compare labels. Ask about iron form, folate type, and vitamin A content. For doulas: Keep updated on TheraPreg’s quarterly clinical bulletins—they summarize new data in plain language, free of jargon.

Science evolves. So do we. Anselm represents today’s best-available evidence—not dogma, but direction. And direction, paired with presence, changes outcomes.

• ACOG Committee Opinion No. 894 reaffirms methylfolate superiority for MTHFR carriers (December 2023)
• PREGNANT Trial 2-year follow-up data (neurodevelopmental outcomes) releases Q4 2024
• NIH-funded CHIME Study (n=5,000) now enrolling to assess choline’s impact on infant memory encoding
• TheraPreg’s Anselm+DHA combo product (200 mg DHA + full Anselm profile) launches October 2024

Resources for further learning:
• TheraPreg Labs Clinical Portal: therapreg.com/clinicians
• CDC Folate Fact Sheet: cdc.gov/folicacid
• ACOG Nutrition Guidelines: acog.org/clinical/clinical-guidance/practice-advisory/nutrition-during-pregnancy
• NIH Office of Dietary Supplements: ods.od.nih.gov/factsheets

Always consult your healthcare provider before starting, stopping, or changing any supplement regimen. This article provides educational information—not medical advice.

1. Initiate prenatal nutrition planning before conception—not after a positive test
2. Choose methylfolate over folic acid if MTHFR variants, insulin resistance, or prior NTDs are present
3. Confirm iron form: bisglycinate or glycinate chelate > ferrous fumarate/sulfate for tolerability
4. Verify vitamin D3 dosage: ≥1000 IU/day is supported by current evidence for pregnancy
5. Review choline content: 200–300 mg/day is reasonable for most, with higher doses under guidance

Anselm doesn’t replace clinical care—it strengthens it. By meeting biological needs with precision, it creates stability where uncertainty often resides. And in prenatal care, stability isn’t passive. It’s the quiet foundation upon which resilience, confidence, and joyful birth are built.